Publication:
Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in thai infants

dc.contributor.authorSriluck Simasathienen_US
dc.contributor.authorSricharoen Migasenaen_US
dc.contributor.authorCoen Beuveryen_US
dc.contributor.authorGijsbert Van Steenisen_US
dc.contributor.authorRudiwilai Samakosesen_US
dc.contributor.authorPunnee Pitisuttithamen_US
dc.contributor.authorTimo Vesikarien_US
dc.contributor.otherPramongkutklao Hospitalen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherNational Institute of Public Health and the Environmenten_US
dc.contributor.otherTampereen Yliopistoen_US
dc.date.accessioned2018-02-27T04:26:52Z
dc.date.available2018-02-27T04:26:52Z
dc.date.issued1994-01-01en_US
dc.description.abstractEnhanced potency inactivated poliovirus vaccine (EIPV), combined with diphtheria-tetanus-pertussis (DTP) vaccine, was compared with oral poliovirus vaccine (OPV) regarding immunogenicity in Thai infants, vaccinated at 2, 4 and 6 months of age. EIPV induced significantly higher seroconversion rates than OPV to all 3 poliovirus types after the second and third immunization. After 3 doses of each vaccine, at 7 months of age, all infants receiving EIPV proved seropositive for poliovirus type 1, type 2 and type 3 neutralizing antibodies, whereas of those receiving OPV, 9% remained seronegative (titre < 1:4) for type 1 (p = 0.0042) and 11% for type 3 (p =0.0013). All participating children were given an additional dose of OPV at the age of 9 months and tested again at 12 months of age. At that point, virtually all infants had poliovirus neutralizing antibodies, but the geometric mean titres to each poliovirus type were significantly higher in the vaccinees who had received EIPV. It is concluded that the greater immunogenicity of EIPV vis-àvis 3 doses of OPV may be biologically significant for protection against poliovirus types 1 and 3 in countries where cases of poliomyelitis occur in young children. These findings warrant considering EIPV, alone or in combination with OPV, for an immunization programme in Thailand and similar countries in the future. © 1994 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.en_US
dc.identifier.citationScandinavian Journal of Infectious Diseases. Vol.26, No.6 (1994), 731-738en_US
dc.identifier.doi10.3109/00365549409008643en_US
dc.identifier.issn00365548en_US
dc.identifier.other2-s2.0-0028600094en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/9598
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0028600094&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleComparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in thai infantsen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0028600094&origin=inwarden_US

Files

Collections